Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €55.32 EUR
Change Today +0.50 / 0.92%
Volume 0.0
8AK On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:44 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Connaught House

1 Burlington Road

Dublin, 4

Ireland

Phone: 353 1 772 8000

Fax:

intain therapeutic medication levels in the body through just one injection every four weeks. The company developed, and markets and sells, VIVITROL in the U.S.; and Cilag GmbH International sells VIVITROL in Russia and the Commonwealth of Independent States. Key Development Programs Aripiprazole Lauroxil Aripiprazole lauroxil is an injectable atypical antipsychotic with one-month and extended-duration formulations in development for the treatment of schizophrenia. Once in the body, aripiprazole lauroxil converts into aripiprazole, which is commercially available under the name ABILIFY. As a long-acting investigational medication based on the company’s proprietary LinkeRx technology, aripiprazole lauroxil is designed to have multiple dosing options and to be administered in a ready-to-use, pre-filled product format. Aripiprazole lauroxil is the company’s first product candidate to leverage its proprietary LinkeRx technology. In April 2014, the company announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. In August 2014, the company submitted an NDA (New Drug Application) to the U.S. Food and Drug Administration (FDA) for aripiprazole lauroxil for the treatment of schizophrenia. The FDA accepted the company’s application for filing in October 2014, and granted the company a Prescription Drug User Fee Act date of August 22, 2015. In December 2014, the company announced the initiation of a phase 1 clinical study of extended dosing intervals of aripiprazole lauroxil in patients with schizophrenia. Results from this phase 1 study are expected mid-2016. ALKS 5461 ALKS 5461 is a proprietary, oral investigational medicine in development for the treatment of major depressive disorder in patients who have an inadequate response to standard antidepressant therapies. ALKS 5461 includes samidorphan in combination with buprenorphine. In March 2014, the company announced the initiation of the pivotal clinical development program for ALKS 5461. In January 2015, the company announced topline results from FORWARD-1, one of a series of supportive clinical studies in the FORWARD phase 3 pivotal program designed to evaluate the safety and tolerability of two titration schedules of ALKS 5461. ALKS 3831 ALKS 3831 is a novel, proprietary investigational medicine designed as an antipsychotic for the treatment of schizophrenia. ALKS 3831 includes samidorphan in combination with the antipsychotic drug olanzapine, which is generally available under the name ZYPREXA. ALKS 3831 is designed to attenuate olanzapine-induced metabolic side effects, including weight gain, and to have utility in the treatment of schizophrenia in patients with alcohol use. In January 2015, the company announced data from the phase 2 study of ALKS 3831 designed to assess the efficacy, safety and tolerability of ALKS 3831 in the treatment of schizophrenia and its attenuation of weight gain, compared to olanzapine. In June 2014, the company announced initiation of a randomized, double-blind, active-controlled phase 2 study to assess ALKS 3831's efficacy, safety and tolerability in treating schizophrenia in patients with alcohol use, compared to olanzapine. The company expects topline results from this study in mid-2017. ALKS 8700 ALKS 8700 is an oral, novel and proprietary monomethyl fumarate (MMF) molecule in development for the treatment of MS. ALKS 8700 is designed to convert to MMF in the body and to offer differentiated features as compared to the marketed dimethyl fumarate, TECFIDERA. In February 2015, the company announced positive topline results from a phase 1, randomized, double-blind clinical study of ALKS 8700, designed to evaluate the safety, tolerability and single-dose pharmacokinetics of various oral formulations of ALKS 8700 compared to both placebo and active control groups. RDB 1419 RDB 1419 is a proprietary, investigational biologic cancer immunotherapy product based on interleukin-2 and its receptors. RDB 1419 is engineered using the company’s proprietary fusion protein technology platform to modulate

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
8AK:GR €55.32 EUR +0.50

8AK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cosmo Pharmaceuticals SA SFr.171.70 CHF +4.00
Emergent Biosolutions Inc $30.80 USD -0.28
Jazz Pharmaceuticals PLC $183.06 USD +2.28
Lupin Ltd 1,735 INR +26.10
Pacira Pharmaceuticals Inc/DE $77.62 USD +0.04
View Industry Companies
 

Industry Analysis

8AK

Industry Average

Valuation 8AK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.0x
Price/Book 6.4x
Price/Cash Flow 373.2x
TEV/Sales 12.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALKERMES PLC, please visit www.alkermes.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.